

## Sareum Holdings PLC

("Sareum" or the "Company")

### Update on SRA737

**Cambridge, UK, 6 March 2023**- Sareum Holdings plc (AIM: SAR), a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, today announces that Sierra Oncology, Inc. ("**Sierra**") (a subsidiary of GSK plc) has completed the return of the Clinical Study Reports and other associated documents and data related to SRA737 to Sareum's co-development partner, the CRT Pioneer Fund LP ("**CPF**").

SRA737 is a clinical-stage oral, selective Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms. It was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, with funding from Sareum and Cancer Research UK.

CPF [acquired](#) worldwide commercial rights to the programme in 2013 as part of a co-development agreement with Sareum. SRA737 was [licensed](#) by CPF to Sierra in September 2016. Sierra progressed SRA737 through Phase 1/2 clinical development and, at the 2019 ASCO Annual meeting, [reported](#) positive preliminary efficacy and safety data from two clinical trials evaluating SRA737 as a monotherapy and in combination with chemotherapy. In addition, preclinical data have been reported that indicate triple drug combinations involving SRA737 may show great promise against hard-to-treat cancers. Sierra has not progressed the asset beyond the Phase 1/2 clinical trial.

Following the acquisition of Sierra by GSK in July 2022, primarily for Sierra's momelotinib myelofibrosis asset, the rights to SRA737 were returned to CPF in January 2023.

Sareum is evaluating potential further development opportunities for SRA737 with CPF and will provide further updates as appropriate.

**Dr Tim Mitchell, CEO of Sareum, commented:** "Our primary focus remains on developing innovative TYK2/JAK1 inhibitors focused on autoimmune disease, including our lead product SDC-1801. We look forward to evaluating the potential development opportunities for SRA737 with CPF and will provide further updates in due course."

- Ends -

### For further information, please contact:

#### Sareum Holdings plc

Tim Mitchell, CEO  
Alex Harrison, Investor Relations

01223 497700  
[ir@sareum.co.uk](mailto:ir@sareum.co.uk)

#### Strand Hanson Limited (Nominated Adviser)

James Dance / James Bellman

020 7409 3494

#### Peel Hunt LLP (Joint Corporate Broker)

James Steel / Oliver Duckworth

020 7418 8900

#### Hybridan LLP (Joint Corporate Broker)

Claire Noyce

020 3764 2341

#### Consillium Strategic Communications (Financial PR)

Jessica Hodgson / Davide Salvi / Stella Lempidaki

0203 709 5700

### About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum is focused on advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors into clinical development as potential new therapies for autoimmune diseases (with an initial focus on psoriasis), respiratory symptoms arising from viral infections and cancer immunotherapy. Sareum is also eligible to receive certain milestone payments and future royalties on SRA737, a clinical-stage, oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. SRA737 was licensed to Sierra Oncology, which was acquired by GSK in June 2022.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at [www.sareum.com](http://www.sareum.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

UPDDXLFBXXLLBBD